The role of medications for the management of patients with NAFLD

Clinics in Liver Disease

Volumn 18, Issue 1, 2014, Pages 73-89

  Mazzella, Natalia ^a   Ricciardi, Laura M ^a   Mazzotti, Arianna ^a   Marchesini, Giulio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anti fibrotic agents; Antioxidants; Drug treatment; Insuin sensitizers; Nonalcoholic fatty liver disease; PPAR agonists

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; CHOLESTEROL; EZETIMIBE; FARNESOID X RECEPTOR; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; LOSARTAN; METFORMIN; OBETICHOLIC ACID; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PIOGLITAZONE; POLYUNSATURATED FATTY ACID; RIMONABANT; ROSIGLITAZONE; SILIBININ; TETRAHYDROLIPSTATIN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ABSORPTION; ANTIOXIDANT ACTIVITY; APOPTOSIS; APPETITE; CHOLESTEROL BLOOD LEVEL; CONTROL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FOLLOW UP; HISTOLOGY; HUMAN; INSULIN RESISTANCE; LIPID OXIDATION; LIVER PROTECTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRACTICE GUIDELINE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION;

ANTI-FIBROTIC AGENTS; ANTIOXIDANTS; DRUG TREATMENT; INSUIN-SENSITIZERS; NONALCOHOLIC FATTY LIVER DISEASE; PPAR AGONISTS;

ANTIOXIDANTS; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 84888063646     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.09.005     Document Type: Review

References (87)

1. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
2. Bugianesi E., Gentilcore E., Manini R., et al. Arandomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
3. Dufour J.F., Oneta C.M., Gonvers J.J., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4:1537-1543.
4. Belfort R., Harrison S.A., Brown K., et al. Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. NEngl J Med 2006, 355:2297-2307.
5. Ratziu V., Giral P., Jacqueminet S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135:100-110.
6. Aithal G.P., Thomas J.A., Kaye P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-1184.
7. Haukeland J.W., Konopski Z., Eggesbo H.B., et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009, 44:853-860.
8. Leuschner U.F., Lindenthal B., Herrmann G., et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52:472-479.
9. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. NEngl J Med 2010, 362:1675-1685.
10. Ratziu V., de Ledinghen V., Oberti F., et al. Arandomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. JHepatol 2011, 54:1011-1019.
11. Torres D.M., Jones F.J., Shaw J.C., et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 2011, 54:1631-1639.
12. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. NEngl J Med 2005, 353:2111-2120.
13. Marchesini G., Brizi M., Bianchi G., et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893-894.
14. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
15. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management ofnon-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142:1592-1609.
16. Mazza A., Fruci B., Garinis G.A., et al. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012, 2012:716404.
17. Shyangdan D., Clar C., Ghouri N., et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 2011, 15:1-110.
18. Loomba R., Lutchman G., Kleiner D.E., et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009, 29:172-182.
19. Gastaldelli A., Harrison S., Belfort-Aguiar R., et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 2010, 32:769-775.
20. Ratziu V., Charlotte F., Bernhardt C., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010, 51:445-453.
21. Lutchman G., Modi A., Kleiner D.E., et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007, 46:424-429.
22. Ratziu V., Caldwell S., Neuschwander-Tetri B.A. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010, 52:2206-2215.
23. Musso G., Cassader M., Gambino R. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 2011, 22:489-496.
24. Schattenberg J.M., Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 2011, 22:479-488.
25. Foster T., Budoff M.J., Saab S., et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011, 106:71-77.
26. Dima A., Marinescu A.G., Dima A.C. Non-alcoholic fatty liver disease and the statins treatment. Rom J Intern Med 2012, 50:19-25.
27. Nseir W., Mograbi J., Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012, 57:1773-1781.
28. Tzefos M., Olin J.L. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. JClin Lipidol 2011, 5:450-459.
29. Chatrath H., Vuppalanchi R., Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012, 32:22-29.
30. Chan D.C., Watts G.F., Gan S.K., et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010, 33:1134-1139.
31. Filippatos T.D., Elisaf M.S. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol 2011, 3:265-267.
32. Park H., Hasegawa G., Shima T., et al. The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. Clin Chim Acta 2010, 411:1735-1740.
33. Fernandez-Miranda C., Perez-Carreras M., Colina F., et al. Apilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008, 40:200-205.
34. Fabbrini E., Mohammed B.S., Korenblat K.M., et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. JClin Endocrinol Metab 2010, 95:2727-2735.
35. Basaranoglu M., Acbay O., Sonsuz A. Acontrolled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. JHepatol 1999, 31:384.
36. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. JHepatol 2007, 47:711-717.
37. Parker H.M., Johnson N.A., Burdon C.A., et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. JHepatol 2013, 56:944-951.
38. Valenzuela R., Espinosa A., Gonzalez-Manan D., et al. N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. PLoS One 2012, 7:e46400.
39. Araya J., Rodrigo R., Pettinelli P., et al. Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. Obesity (Silver Spring) 2010, 18:1460-1463.
40. Zhu F.S., Liu S., Chen X.M., et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008, 14:6395-6400.
41. Shapiro H., Tehilla M., Attal-Singer J., et al. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr 2011, 30:6-19.
42. Capanni M., Calella F., Biagini M.R., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006, 23:1143-1151.
43. Spadaro L., Magliocco O., Spampinato D., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008, 40:194-199.
44. Tanaka N., Sano K., Horiuchi A., et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. JClin Gastroenterol 2008, 42:413-418.
45. Zelber-Sagi S., Kessler A., Brazowsky E., et al. Adouble-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639-644.
46. Harrison S.A., Fecht W., Brunt E.M., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009, 49:80-86.
47. Peng L., Wang J., Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev 2011, (6). CD003619.
48. Pietu F., Guillaud O., Walter T., et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol 2012, 36:146-155.
49. Lavine J.E., Schwimmer J.B., Molleston J.P., et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010, 31:62-70.
50. Harrison S.A., Torgerson S., Hayashi P., et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98:2485-2490.
51. Zein C.O., Yerian L.M., Gogate P., et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011, 54:1610-1619.
52. Satapathy S.K., Sakhuja P., Malhotra V., et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. JGastroenterol Hepatol 2007, 22:634-638.
53. Lee Y.M., Sutedja D.S., Wai C.T., et al. Arandomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008, 2:196-201.
54. Zein C.O., Lopez R., Fu X., et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012, 56:1291-1299.
55. Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol 2012, 36(Suppl 1):S41-S45.
56. Pathil A., Mueller J., Warth A., et al. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 2012, 55:1369-1378.
57. Kong B., Luyendyk J.P., Tawfik O., et al. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. JPharmacol Exp Ther 2009, 328:116-122.
58. Zhang Y., Edwards P.A. FXR signaling in metabolic disease. FEBS Lett 2008, 582:10-18.
59. Adorini L., Pruzanski M., Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012, 17:988-997.
60. Mudaliar S., Henry R.R., Sanyal A.J., et al. Efficacy and safety of the farnesoid Xreceptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013, 145(3):574-582.e1.
61. Pedersen J., Holst J.J. Glucagon like-peptide 1 receptor and the liver. Liver Int 2011, 31:1243-1245.
62. Balaban Y.H., Korkusuz P., Simsek H., et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007, 6:242-250.
63. Yilmaz Y., Atug O., Yonal O., et al. Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease. Med Sci Monit 2009, 15:HY1-HY5.
64. Kern M., Kloting N., Niessen H.G., et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One 2012, 7:e38744.
65. Ding X., Saxena N.K., Lin S., et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43:173-181.
66. Son J.P., Son M.K., Jun S.W., et al. Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice. Pharmazie 2013, 68:58-62.
67. Mells J.E., Fu P.P., Sharma S., et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012, 302:G225-G235.
68. Shirakawa J., Fujii H., Ohnuma K., et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011, 60:1246-1257.
69. Kenny P.R., Brady D.E., Torres D.M., et al. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 2010, 105:2707-2709.
70. Lee J., Hong S.W., Rhee E.J., et al. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab J 2012, 36:262-267.
71. Liu S., Hatano B., Zhao M., et al. Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation. JBiol Chem 2011, 286:1237-1247.
72. Lee M.Y., Choi R., Kim H.M., et al. Peroxisome proliferator-activated receptor delta agonist attenuates hepatic steatosis by anti-inflammatory mechanism. Exp Mol Med 2012, 44:578-585.
73. Riserus U., Sprecher D., Johnson T., et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57:332-339.
74. Iwaisako K., Haimerl M., Paik Y.H., et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. Proc Natl Acad Sci USA 2012, 109:E1369-E1376.
75. Nagasawa T., Inada Y., Nakano S., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006, 536:182-191.
76. Wu H.T., Chen C.T., Cheng K.C., et al. Pharmacological activation of peroxisome proliferator-activated receptor delta improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice. Horm Metab Res 2011, 43:631-635.
77. Cariou B., Zair Y., Staels B., et al. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011, 34:2008-2014.
78. Cariou B., Hanf R., Lambert-Porcheron S., et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013, 36:2923-2930.
79. Staels B., Rubenstrunk A., Noel B., et al. Hepato-protective effects of the dual PPARalpha/delta agonist GFT505 in rodent models of NAFLD/NASH. Hepatology 2013, [Epub ahead of print].
80. Kashi M.R., Torres D.M., Harrison S.A. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:396-406.
81. Mallat A., Lotersztajn S. Endocannabinoids and their role in fatty liver disease. Dig Dis 2010, 28:261-266.
82. Durazzo M., Belci P., Collo A., et al. Focus on therapeutic strategies of nonalcoholic fatty liver disease. Int J Hepatol 2012, 2012:464706.
83. Yokohama S., Yoneda M., Haneda M., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
84. Barry-Hamilton V., Spangler R., Marshall D., et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010, 16:1009-1017.
85. Schuppan D., Gorrell M.D., Klein T., et al. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010, 30:795-808.
86. Sanyal A.J., Brunt E.M., Kleiner D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54:344-353.
87. Nascimbeni F., Pais R., Bellentani S., et al. From NAFLD in clinical practice to answers from guidelines. JHepatol 2013, 59:859-871.